Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer - PubMed (original) (raw)
Comparative Study
Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer
G G Van den Eynden et al. Breast Cancer Res Treat. 2004 May.
Free article
Abstract
Aims: Inflammatory breast cancer (IBC) is an aggressive subtype of breast cancer with poor prognosis. The mechanisms responsible for the aggressive clinical evolution are incompletely understood. We constructed a tissue microarray (TMA) and validated its use in translational IBC research. Differential expression of proteins that might play a role in causing the IBC phenotype was studied.
Methods and results: A TMA containing 34 IBC and 41 non-stage matched non-IBC tumours was constructed. Five core biopsies were taken for each IBC and three cores for each non-IBC tumour. The TMA was validated using three approaches: (1) the excellent concordance between immunohistochemical results of the initial pathological examination and the results obtained with the TMA for ER, PR and HER2/neu (kappa > 0.74); (2) the known differential expression between IBC and non-IBC for four bio-markers in IBC (ER, PR, p53 and HER2/neu) was confirmed ( p < 0.01); (3) the HER2/neu status using three different antibodies (CB11, TAB250 and HercepTest) was highly concordant (kappa > 0.75). Furthermore, the overexpression of E-Cadherin and RhoC GTPase in IBC ( p < 0.05) was confirmed. We did not find a differential expression pattern for carbonic anhydrase IX (CA IX) and EGFR.
Conclusions: Using different approaches, we have validated the use of our TMA for studying differential protein expression in IBC and non-IBC. We confirm the overexpression of E-Cadherin and RhoC GTPase in IBC. The lack of differential expression for CA IX and EGFR might suggest the pathways are equally utilised in both types of breast cancer.
Similar articles
- Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer.
Van den Eynden GG, Van Laere SJ, Van der Auwera I, Merajver SD, Van Marck EA, van Dam P, Vermeulen PB, Dirix LY, van Golen KL. Van den Eynden GG, et al. Breast Cancer Res Treat. 2006 Feb;95(3):219-28. doi: 10.1007/s10549-005-9002-1. Epub 2005 Oct 22. Breast Cancer Res Treat. 2006. PMID: 16244790 - Persistent E-cadherin expression in inflammatory breast cancer.
Kleer CG, van Golen KL, Braun T, Merajver SD. Kleer CG, et al. Mod Pathol. 2001 May;14(5):458-64. doi: 10.1038/modpathol.3880334. Mod Pathol. 2001. PMID: 11353057 - Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA-binding.
Van Laere SJ, Van der Auwera I, Van den Eynden GG, Elst HJ, Weyler J, Harris AL, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. Van Laere SJ, et al. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3249-56. doi: 10.1158/1078-0432.CCR-05-2800. Clin Cancer Res. 2006. PMID: 16740744 - [High-throughput quantification of tissue microarrays: identification of candidate target proteins in inflammatory breast cancer].
Taranger-Charpin C, Andrac-Meyer L, Dales JP, Carpentier-Meunier S, Andonian C, Lavaut MN, Allasia C, Bonnier P. Taranger-Charpin C, et al. Bull Acad Natl Med. 2007 Feb;191(2):361-74; discussion 374-6. Bull Acad Natl Med. 2007. PMID: 17969554 Review. French. - The patient advocate view.
Johnson GO, Kirschenbaum M, Mason G, Rush LR. Johnson GO, et al. Breast Dis. 2005-2006;22:3-8. doi: 10.3233/bd-2006-22102. Breast Dis. 2005. PMID: 16735782 Review.
Cited by
- The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy.
Neophytou CM, Pierides C, Christodoulou MI, Costeas P, Kyriakou TC, Papageorgis P. Neophytou CM, et al. Front Oncol. 2020 Jun 9;10:899. doi: 10.3389/fonc.2020.00899. eCollection 2020. Front Oncol. 2020. PMID: 32656079 Free PMC article. Review. - Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer.
Manai M, Doghri R, Finetti P, Mrad K, Bouabsa R, Manai M, Birnbaum D, Bertucci F, Charfi L, Driss M. Manai M, et al. In Vivo. 2020 Jan-Feb;34(1):177-184. doi: 10.21873/invivo.11759. In Vivo. 2020. PMID: 31882477 Free PMC article. - Macrophages Enhance Migration in Inflammatory Breast Cancer Cells via RhoC GTPase Signaling.
Allen SG, Chen YC, Madden JM, Fournier CL, Altemus MA, Hiziroglu AB, Cheng YH, Wu ZF, Bao L, Yates JA, Yoon E, Merajver SD. Allen SG, et al. Sci Rep. 2016 Dec 19;6:39190. doi: 10.1038/srep39190. Sci Rep. 2016. PMID: 27991524 Free PMC article. - Inflammatory breast cancer: New factors contribute to disease etiology: A review.
Mohamed MM, Al-Raawi D, Sabet SF, El-Shinawi M. Mohamed MM, et al. J Adv Res. 2014 Sep;5(5):525-36. doi: 10.1016/j.jare.2013.06.004. Epub 2013 Jun 14. J Adv Res. 2014. PMID: 25685520 Free PMC article. Review. - Tissue microarray-based evaluation of Chromatin Assembly Factor-1 (CAF-1)/p60 as tumour prognostic marker.
Mascolo M, Ilardi G, Merolla F, Russo D, Vecchione ML, De Rosa G, Staibano S. Mascolo M, et al. Int J Mol Sci. 2012;13(9):11044-11062. doi: 10.3390/ijms130911044. Epub 2012 Sep 5. Int J Mol Sci. 2012. PMID: 23109837 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous